DOSAGE INDEX / SINGLE
Thymosin Alpha-1
Research, reported schedules and supply planning.
Review thymosin alpha-1 sepsis trials, hepatitis B studies, vaccine-response research and safety concerns with clear evidence limits.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 300–500 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
Titration & progression
The phases below describe the named source example, not an instruction to increase a dose. Product-label schedules and research examples are identified separately.
| Phase | Amount per administration | Frequency |
|---|---|---|
| Days 1–7 | 0.3 mg | Daily |
| Days 8–56 | 0.5 mg | Daily |
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
Source example: 56-day planning window: 26.6 mg total material. Use this total below, or enter a different documented total for comparison.
| Vial strength | Vials needed |
|---|---|
| 5 mg | 6 |
| 10 mg | 3 |
Calculated from the displayed schedule.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- The 2025 TESTS trial randomized 1,106 adults with sepsis across 22 Chinese centers. Its modified intention-to-treat analysis included 1,089 participants. Death by day 28 occurred in 23.4% of the thymosin alpha-1 group and 24.1% of the placebo group. The corrected hazard ratio was 0.97, with a 95% confidence interval of 0.76 to 1.24 and P=.82. The trial did not demonstrate an overall survival benefit. [2]
- The 2013 ETASS trial randomized 361 patients with severe sepsis in six Chinese hospitals. Reported 28-day mortality was 26% with thymosin alpha-1 and 35% in controls. The non-stratified comparison had P=.062, while the survival analysis reported P=.049. The relative-risk confidence interval, 0.54 to 1.02, included 1. [4]
- A pilot study in people receiving hemodialysis compared influenza vaccination alone with vaccination plus thymosin alpha-1. The intention-to-treat population included 94 participants. Antibody measurements at day 21 favored combination groups on some measures, but responses declined rapidly by day 42. The reported outcomes were laboratory measures of vaccine response. [7]
- FDA's safety discussion for compounded thymosin alpha-1 identifies potential immunogenicity concerns for certain routes, peptide impurities and difficulties characterizing the active ingredient. It states that available safety information is inadequate to understand the extent of the issues for the proposed compounded drug. [9]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 32 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Original sequence and characterization paper
- Original TESTS publication
- Published correction
- Original ETASS trial
- Original hepatitis B study
- Original placebo-controlled phase 3 trial
- Original hemodialysis vaccine study
- Original elderly-volunteer study
- FDA safety assessment page
- World Journal of VirologyFurther reading · Listed in reference bibliography.
- Molecules (MDPI)Further reading · Listed in reference bibliography.
- InflammopharmacologyFurther reading · Listed in reference bibliography.
- Expert Opinion on Biological TherapyNo destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
- Annals of the New York Academy of SciencesFurther reading · Listed in reference bibliography.
- Clinical ImmunologyFurther reading · Listed in reference bibliography.
- FDA Peptide Advisory Committee (2024)No destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
- Hospital PharmacyFurther reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- Johns Hopkins Arthritis CenterGeneral guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Subcutaneous Drug Injection Review (PMC)Further reading · Listed in reference bibliography.
- Phase 3 TESTS Thymosin Alpha-1 Sepsis Trial, PMID 39814420 - Primary 1,106-person study using 1.6 mg SC every 12 hours for seven days after reconstitution in 1 mL sterile water.Further reading · Listed in reference bibliography.
- ETASS Severe Sepsis Trial - Primary trial using 1.6 mg SC twice daily for five days and once daily for two days.Further reading · Listed in reference bibliography.
- Zadaxin HIV Immunologic-Nonresponder Trial - Primary study using 1.6 mg SC daily for two weeks and then twice weekly for 22 weeks.Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.